Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced β-cell damage

Nephrology Dialysis Transplantation

Volumn 20, Issue 11, 2005, Pages 2311-2315

  Hjelmesæth, Jøran ^a,b   Müller, Fredrik ^a   Jenssen, Trond ^a   Rollag, Halvor ^a   Sagedal, Solbjørg ^a   Hartmann, Anders ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Hospital in Vesfold HF   (Norway)

Author keywords

Cytomegalovirus infection; Posttransplantation diabetes mellitus; Risk factor

Indexed keywords

CALCINEURIN INHIBITOR; GAMMA INTERFERON; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 6; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ALPHA; VALACICLOVIR;

CELL DAMAGE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DATA ANALYSIS; DIABETES MELLITUS; DIABETOGENESIS; DRUG MEGADOSE; EDITORIAL; EMBASE; GRAFT FAILURE; HEPATITIS C; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDLINE; NEUTROPHIL CHEMOTAXIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VIREMIA;

ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DIABETES MELLITUS, TYPE 2; DNA, VIRAL; HUMANS; INSULIN-SECRETING CELLS; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; RISK FACTORS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 27644566722     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi033     Document Type: Editorial

References (40)

1. Jaeckel E, Manns M, van Herrath M. Viruses and diabetes. Ann NY Acad Sci 2002; 958: 7-25
2. Fabrizi F, Lampertico P, Lunghi G, Mangano S, Aucella F, Martin P. Review article: Hepatitis C virus infection and type-2 diabetes mellitus in renal diseases and transplantation. Aliment Pharmacol Ther 2005; 21: 623-632
3. Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004; 41: 132-138
4. Hjelmesæth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-983
5. Hjelmesæth J, Sagedal S, Hartmann A et al. Asymptomatic cytomegalovirus infection is associated with increased risk for new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550-1556
6. Hjelmesæth J, Jenssen T, Hagen M, Egeland T, Hartmann A. Determinants of insulin secretion after renal transplantation. Metabolism 2003; 52: 573-578
7. Sharma RK, Prakash R, Jeloka T et al. Posttransplant diabetes mellitus in renal transplant recipients-a single center experience. Transplant Proc 2003; 35: 266-267
8. Lehr H, Jao S, Waltzer WC, Anaise D, Rapaport FT. Cytomegalovirus-induced diabetes mellitus in a renal transplant recipient. Transplant Proc 1985; 17: 2152-2154
9. Weller TH, Macauley JC, Craig JM, Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med 1957; 94: 4-12
10. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-337
11. Ljungman P, Griffiths P, Paya C. Definition of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097
12. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75: SS3-SS24
13. Hjelmesæth J, Sagedal S, Hartmann A et al. Cytomegalovirus infection is associated with increased risk for new-onset diabetes and impaired insulin release after renal transplantation. J Am Soc Nephrol 2003; 14 [Abstract]: PO487
14. Burak KW, Kremers WK, Batts KP et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369
15. Rosen HR, Chou S, Corless CL et al. Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721-726
16. Gomez E, Gallaraga MC, de Ona M et al. Association between cytomegalovirus antigenemia and hepatitis C virus-RNA in HCV seropositive renal transplants. Transplant Proc 2002; 34: 65-66
17. Bissinger AL, Sinzger C, Kaiserling E, Jahn G. Human cytomegalovirus as a direct pathogen: Correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J Med Virol 2002; 67: 200-206
18. Pak CY, Eun HM, McArthur RG, Yoon JW. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988; 2: 1-4
19. Lohr JM, Oldstone MB. Detection of cytomegalovirus nucleic acid sequences in pancreas in type 2 diabetes. Lancet 1990; 336: 644-648
20. Hattersley AT, Lo YM, Read SJ, Eglin RP, Wainscoat JS, Clark A. Failure to detect cytomegalovirus DNA in pancreas of type 2 diabetes. Lancet 1992; 339: 459-460
21. Mocarski ES. Immunomodulation by cytomegaloviruses: Manipulative strategies beyond evasion. Trends Microbiol 2002; 10: 332-339
22. Sindre H, Rollag H, Olafsen MK, Degre M, Hestdal K. Human cytomegalovirus induces apoptosis in the hematopoietic cell line MO7e. APMIS 2000; 108: 223-230
23. van den Berg AP, Meyaard L, Otto SA et al. Cytomegalovirus infection associated with a decreased proliferative capacity and increased rate of apoptosis of peripheral blood lymphocytes. Transplant Proc 1995; 27: 936-938
24. Hiemstra HS, Schloot NC, van Veelen PA et al. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proc Natl Acad Sci USA 2001; 98: 3988-3991
25. Santamaria P, Nakleh RE, Sutherlad DE, Barbosa JJ. Characterization of T lymphocytes infiltrating human pancreas allograft affected by isleitis and recurrent diabetes. Diabetes 1992; 41: 53-61
26. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55: 1139-1149
27. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and β-cell function: Potential role of adipocyte derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 [Suppl 3]: 24-34
28. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110
29. Vives-Pi M, Somoza N, Fernandez-Alvarez J et al. Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MN-2 and of sensitivity to endotoxin (LPS) in islet β cells. Clin Exp Immunol 2003; 133: 208-218
30. Compton T. Receptors and immune sensors: The complex entry path of human cytomegalovirus. Trends Cell Biol 2004; 14: 5-8
31. Dengler TJ, Raftery MJ, Werle M, Zimmermann R, Schonrich G. Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin-1β. Transplantation 2000; 69: 1160-1168
32. Hohmeier HE, Tran VV, Chen G, Gasa R, Newgard CB. Inflammatory mechanisms in diabetes: Lessons from the β-cell. Int J Obes Relat Metab Disord 2003; 27: S12-S16
33. Yurochko AD, Huang E-S. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J Immunol 1999; 162: 4806-4816
34. Movahedi B, van de Casteele M, Caluwé N et al. Human pancreatic duct cells can produce tumour necrosis factor-a that damages neighbouring beta cells and activates dendritic cells. Diabetologia 2004; 47: 998-1008
35. + T cells during primary cytomegalovirus infection. J Clin Invest 2000; 105: 541-548
36. Essa S, Raghupathy R, Pacsa AS, El-Shazly A, Said T. Changes in cell-mediated immunity in kidney transplant recipients with active CMV infection. FEMS Immunol Med Microbiol 2002; 32: 199-204
37. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462-1470
38. Koetz AC, Delbruck R, Furtwangler A et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: A prospective, double-blind, placebo-controlled study. Transplantation 2001; 72: 1325-1327
39. Sagedal S, Nordal KP, Hartmann A et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: A randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899-1908
40. Liu CL, Fan ST, Lo CM et al. Interleukin-2 receptor antibody (Basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transplant 2004; 10: 728-733